Research Grant To Wistar Institute Involves Linda Creed Breast Cancer Foundation In Breast Cancer Research

December 07, 1998

Philadelphia--For the second year in a row, The Wistar Institute medical research laboratory of Daniela Santoli, Ph.D., has been awarded a Linda Creed Breast Cancer Foundation grant. The $20,000 award will support continued research on TALL-104 cells, which show promise in the treatment of breast cancer.

According to Lisa Brownstein, President of the Linda Creed Breast Cancer Foundation, this grant allows the Foundation "to be involved in a small way in research and clinical trials for new treatments and perhaps a cure for breast cancer. We feel that this funding is an important part of our commitment to the women of our community."

The Linda Creed Breast Cancer Foundation was established in memory of Linda Creed, a songwriter and former resident of the Mt. Airy section of Philadelphia, who died in 1986 of breast cancer. The group is dedicated to finding a cure for breast cancer and provides support for those research efforts that seem most promising.

In pre-clinical studies using pets volunteered by desperate owners, TALL-104 "killer" cells successfully caused the regression and disappearance of tumors without producing side effects or damaging normal tissues. Over the past 12 months, they also were tested in Phase I clinical trials on children with leukemias and solid tumors, and on women with breast cancer. The trials demonstrated that high doses of TALL-104 cells can be administered without toxicity to patients.

Although these early phase trials were not designed to test the anti-tumor efficacy of TALL-104 cells, encouraging preliminary evidence indicates their ability to induce a reduction of tumor load.

Dr. Santoli and her research team are currently planning a Phase I-II trial to identify the kinds of tumors most responsive to TALL-104 cells, and to test treatment regimens that would be most beneficial to patients. They also are looking at ways of increasing the cells' ability to target specific tumors.

The Phase I clinical trial on women with breast cancer is being funded by the U.S. Army Breast Cancer Research Program (Department of Defense). Current funding for Dr. Santoli's related breast cancer research is being provided by the Elsa U. Pardee Foundation.
-end-
The Wistar Institute, established in 1892, was the first independent medical research facility in the country. For more than 100 years, Wistar scientists have been making history and improving world health through their development of vaccines for diseases that include rabies, German measles, infantile gastroenteritis (rotavirus), and cytomegalovirus; discovery of molecules like interleukin-12, which are helping the immune system fight bacteria, parasites, viruses and cancer; and location of genes that contribute to the development of diseases like breast, lung and prostate cancer. Wistar is a National Cancer Institute Cancer Center.
-end-


The Wistar Institute

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.